Tigason - Etretinate

Tigason (Etretinate). Roche Products Ltd ABPI Datasheet Compendium, 1993-1994, p. 1347-... 

Jagell, S. and Liden, S., Treatment of the ichthyosis of the Sjogren-Larsson syndrome with etretinate (Tigason ), Acta Derm. Venereol., 63, 89-91, 1983. 

In 1990, etretinate (Tigason) was replaced by acitretin (Neo-Tigason), an aromatic retinoid, a carboxylic acid metabolite of etretinate (15). It is effective in pustular psoriasis and psoriatic palmoplantar keratoderma and in combination with PUVA or topical therapy (calci-potriol or glucocorticoids) in the treatment of other forms of psoriasis. It has also been used to treat disorders of keratinization (ichthyosis, palmoplantar keratoderma, Darier s disease) and severe cutaneous forms of lichen planus. It prevents new skin carcinomas in patients with xeroderma pigmentosum and those who are immunosuppressed. The main advantage of acitretin is its short half-life of 50 hours, compared with over 80 days for etretinate (16). 

---